To evaluate the prognostic potential for NSD3 expression in PAAD, we analyzed clinical specimens by IHC and found that NSD3 immunostained signals in PAAD tissue were markedly different between samples (Figure 4A). The gene discussed is NSD3; the disease is pancreatic adenocarcinoma.